2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168981
    Larubrilstat 2765226-31-9 98%
    Larubrilstat is a vascular non-inflammatory molecule-1 (VNN1) inhibitor.
    Larubrilstat
  • HY-169026
    DCN1-IN-2 2543578-57-8 98%
    DCN1-IN-2 is a DCN1 inhibitor with an IC50 value of 2.96 nM. DCN1-IN-2 can alleviate Ang II/TGFβ-induced activation of cardiac fibroblasts. DCN1-IN-2 can reduce ISO-induced cardiac fibrosis and remodeling in mice by selectively inhibiting cullin 3.
    DCN1-IN-2
  • HY-169028
    8-Iso prostaglandin E2 isopropyl ester 330589-21-4 98%
    8-Iso prostaglandin E2 isopropyl ester is a more lipophilic form of the free acid, 8-iso Prostaglandin E2.
    8-Iso prostaglandin E2 isopropyl ester
  • HY-169037
    Δ8-Tetrahydrocannabinoquinone 19542-59-7 98%
    Δ8-Tetrahydrocannabinoquinone (HU-336) is a potent antiangiogenic agent. Δ8-Tetrahydrocannabinoquinone inhibits angiogenesis by directly inducing apoptosis of vascular endothelial cells without changing the expression of pro- and antiangiogenic cytokines and receptors. Δ8-Tetrahydrocannabinoquinone is highly effective against tumor xenografts in nude mice.
    Δ8-Tetrahydrocannabinoquinone
  • HY-169052
    Cyy-272 2644673-01-6 98%
    Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 can be used in the study of obese cardiomyopathy.
    Cyy-272
  • HY-16910G
    WIKI4 (GMP) 838818-26-1 98%
    WIKI4 (GMP) is WIKI4 (HY-16910) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. WIKI4 is a potent tankyrase inhibitor.
    WIKI4 (GMP)
  • HY-169155
    OsMo 98%
    OsMo is a lysosome-targeting hNEU1 inhibitor that can be used in the study of myocardial injury.
    OsMo
  • HY-169241
    B3 98%
    B3 is an isotope-labeled active compound suitable for the study of hypertrophic cardiomyopathy.
    B3
  • HY-169251
    α-Glucosidase-IN-75 98%
    α-Glucosidase-IN-75 (compound 13) is an α-glucosidase inhibitor with an IC50 of 3.81 μM. α-Glucosidase-IN-75 can be used for the study of high glucose-induced cardiovascular diseases.
    α-Glucosidase-IN-75
  • HY-169314
    JNK-IN-19 3059122-56-1 98%
    JNK-IN-19 (Compound Q8) is a c-Jun N-terminal kinase inhibitor that is used for treating and/or preventing an injury before, during, or after a surgical procedure.
    JNK-IN-19
  • HY-169575
    PARP1-IN-36 1606996-12-6 98%
    PARP1-IN-36 (compound 11) is a 4-carboxamido-isoindolinone derivative and a selective PARP-1 inhibitor with a Kd < 0.01 μM. PARP1-IN-36 can be utilized in cancer, cardiovascular diseases, nervous system injury and inflammation research.
    PARP1-IN-36
  • HY-169624
    GPV574 635703-12-7 98%
    GPV574 is a derivative of the antiarrhythmic compound propafenone, capable of inhibiting HERG channels (IC50 = 5.04 μM).
    GPV574
  • HY-169761
    (rac)-dWIZ-1 2879251-63-3 98%
    WIZ-IN-1 (Example 2) is a Wiz inhibitor (DC50: 0.36 μM). WIZ-IN-1 can be used for research of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta- hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    (rac)-dWIZ-1
  • HY-169803
    L-657926 113243-00-8 98%
    L-657926 is a stereoselective antagonist of the thromboxane A2 (TxA2) receptor, composed of (-)-9-chlorobenzyl-6-fluoro-1,2,3,4-tetrahydrocarbazol-1-yl acetic acid and (+)-9-chlorobenzyl-6-fluoro-1,2,3,4-tetrahydrocarbazol-l-yl acetic acid. The IC50s of (-) and (+) configurations for TxA2 are 0.27 nM and 124 nM, respectively.
    L-657926
  • HY-169813
    Yakuchinone B 81840-57-5 98%
    Yakuchinone B is an Acyl-CoA: cholesterol O-acyltransferase (ACAT) inhibitor with hypocholesterolemic activity, which is found in the seeds of Zingiberaceae. Yakuchinone B inhibits rat hepatic ACAT with an IC50 value of 20.6 μM. Yakuchinone B is promising for research of hypercholesterolemia and atherosclerosis.
    Yakuchinone B
  • HY-169824
    TRPML modulator 1 2171065-77-1 98%
    TRPML modulator 1 (compound A12) is a TRPML modulator that promotes autophagy. TRPML modulator 1 AC50 in the TFEB test is less than 2 mM.
    TRPML modulator 1
  • HY-169827
    EMD-132338 167364-01-4 98%
    EMD-132338 is a GPIIb/IIIa (αIIbβ3) antagonist that inhibits platelet aggregation. EMD-132338 can be utilized in antithrombosis research.
    EMD-132338
  • HY-17003R
    Saquinavir mesylate (Standard) 149845-06-7
    Saquinavir mesylate (Standard) (Ro 31-8959/003 (Standard)) is the analytical standard of Saquinavir mesylate (HY-17003). This product is intended for research and analytical applications. Saquinavir (Ro 31-8959) mesylate is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir mesylate also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
    Saquinavir mesylate (Standard)
  • HY-17005R
    Olmesartan medoxomil (Standard) 144689-63-4 99.68%
    Olmesartan medoxomil (Standard) is the analytical standard of Olmesartan medoxomil. This product is intended for research and analytical applications. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM.
    Olmesartan medoxomil (Standard)
  • HY-17005S
    Olmesartan medoxomil-d6 1127298-67-2 98%
    Olmesartan medoxomil-d6 (CS 866-d6) is the deuterium labeled Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM.
    Olmesartan medoxomil-d6
Cat. No. Product Name / Synonyms Application Reactivity